

VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via first class mail in an envelope addressed to the U.S. PTO, Box: Sequence, P.O. Box 2327, Arlington, VA 22202 on June 26, 2002.

Fulbright & Jaworski L.L.P.

LUD 5752 DIV JEL/NDH (10109097)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Jean-Christophe Renauld, et al.

Serial No

10/026,106

Filed

December 21, 2001

For

ISOLATED CYTOKINE RECEPTOR LICR-2

Art Unit

UNKNOWN

Examiner

**UNKNOWN** 

June 26, 2002

U.S. Patent and Trademark Office

Box: Sequence P.O. Box 2327

Arlington, VA 22202

## **RESPONSE TO SEQUENCE LETTER**

SIR:

Responsive to the letter dated June 10, 2002, a copy of which is attached, please replace the current paper copy and computer readable forms of sequence information with the attached.

The undersigned hereby declares that, to the best of his knowledge, the paper copy and computer readable forms of sequence information are identical to each other and to information set forth in the application as filed. No new matter is believed presented.

Respectfully submitted,

FULBRIGHT & JAWQRSKI/L.L.P.

Norman D. Hanson, Esc. Registration No. 30,946

666 Fifth Avenue New York, New York 10103-3198

25182240.1



## United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT   | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-------------------------|------------------------|
| 10/026,106         | 12/21/2001          | Jean-Christophe Renauld | LUD-5752 DIV JEL/NDH   |

24972 FULBRIGHT & JAWORSKI, LLP 666 FIFTH AVE NEW YORK. NY 10103-3198 CONFIRMATION NO. 7513
FORMALITIES LETTER
OC000000008256937\*

Date Mailed: 06/10/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE